Author + information
- Received June 28, 2016
- Revision received November 11, 2016
- Accepted December 15, 2016
- Published online April 24, 2017.
- Reka Zsilinszka, MDa,
- Robert J. Mentz, MDb,
- Adam D. DeVore, MD, MHSb,
- Zubin J. Eapen, MDb,
- Peter S. Pang, MDc and
- Adrian F. Hernandez, MD, MHSb,∗ ()
- aDuke University School of Medicine, Durham, North Carolina
- bDivision of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina
- cDepartment of Emergency Medicine and the Regenstrief Institute, Indiana University School of Medicine, Indianapolis, Indiana
- ↵∗Address for correspondence:
Dr. Adrian F. Hernandez, Duke Clinical Research Institute, P.O. Box 17969, Durham, North Carolina 27715.
Acute heart failure (HF) is a major public health problem with substantial associated economic costs. Because most patients who present to hospitals are admitted irrespective of their level of risk, novel approaches to manage acute HF are needed, such as the use of same-day access clinics for outpatient diuresis and observation units from the emergency department. Current published data lacks a comprehensive overview of the present state of acute HF management in various clinical settings. This review summarizes the strengths and limitations of acute HF care in the outpatient and emergency department settings. Finally, a variety of innovative technologies that have the potential to improve acute HF management are discussed.
Dr. Hernandez was supported, in part, by funding from the Agency for Healthcare Research and Quality (U19HS021092). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. Dr. Mentz has received research funding from the National Institutes of Health, Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Novartis, Otsuka, Medtronic, and ResMed; and honoraria from Thoratec and Heartware. Dr. DeVore has received research support from Amgen, Novartis, and the American Heart Association; and has consulted for Maquet. Dr. Eapen has served on advisory boards for Novartis, Medtronic, and Cytokinetics; consulted for Novartis, Myokardia, SHL Telemedicine, and Janssen; and received honoraria from Janssen. Dr. Pang has consulted for Bristol-Myers Squibb, Intersection Medical Janssen, Medtronic, Novartis, Trevena, scPharmaceuticals, Cardioxyl, Roche Diagnostics, and Relypsa; received research support from Roche, Novartis, PCORI, IUSM, and Indianapolis EMS; and received honoraria from Palatin Technologies. Dr. Hernandez has received research funding from Amgen, AstraZeneca, GlaxoSmithKline, Merck, and Novartis; and consulted for AstraZeneca, Merck, and Novartis. Dr. Zsilinszka has reported no relationships relevant to the contents of this paper to disclose. John R. Teerlink, MD, served as Guest Editor for this paper.
- Received June 28, 2016.
- Revision received November 11, 2016.
- Accepted December 15, 2016.
- 2017 American College of Cardiology Foundation